Stocks and Investing
Stocks and Investing
Wed, October 5, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Coleman Downgraded (CC) to Hold on, Oct 5th, 2022
David Coleman of Argus Research, Downgraded "The Chemours Company" (CC) to Hold on, Oct 5th, 2022.
David has made no other calls on CC in the last 4 months.
There are 5 other peers that have a rating on CC. Out of the 5 peers that are also analyzing CC, 3 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Leithead of "Barclays" Maintained at Hold with Decreased Target to $30 on, Tuesday, September 27th, 2022
- Joshua Spector of "UBS" Maintained at Hold with Increased Target to $37 on, Friday, July 29th, 2022
- Matthew DeYoe of "B of A Securities" Downgraded from Strong Buy to Hold and Decreased Target to $44 on, Tuesday, June 14th, 2022
These are the ratings of the 2 analyists that currently disagree with David
- John McNulty of "BMO Capital" Maintained at Buy with Decreased Target to $46 on, Friday, September 23rd, 2022
- Arun Viswanathan of "RBC Capital" Maintained at Buy with Decreased Target to $35 on, Thursday, September 22nd, 2022
Contributing Sources